5:56 PM
 | 
Apr 08, 2008
 |  BC Extra  |  Company News

Russia approves Oncophage

Antigenics (NASDAQ:AGEN) was up $0.56 (23%) to $3.03 on Tuesday after the Russian Ministry of Public Health approved Oncophage vitespen to treat kidney cancer patients at intermediate risk...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >